Cumbo Alexander
Known title: President and CEOCIK: 0001685994
Associated companies
Transaction History
| SLDB | ▼ Sell | Open Market | 16,644 | $97K | 2/18/2026 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 30,031 | — | 2/13/2026 | View on chart |
| SLDB | ▼ Sell | Open Market | 48,913 | $315K | 2/4/2026 | View on chart |
| SLDB | ▼ Sell | Open Market | 80,258 | $517K | 2/2/2026 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 100,400 | — | 1/31/2026 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 169,401 | — | 1/29/2026 | View on chart |
| SLDB | ▼ Sell | Open Market | 10,808 | $55K | 12/3/2025 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 28,612 | — | 12/2/2025 | View on chart |
| SLDB | ▼ Sell | Open Market | 11,365 | $45K | 2/14/2025 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 30,031 | — | 2/13/2025 | View on chart |
| SLDB | ▼ Sell | Open Market | 11,114 | $62K | 12/3/2024 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 28,612 | — | 12/2/2024 | View on chart |
| SLDB | ▼ Sell | Open Market | 11,757 | $33K | 12/4/2023 | View on chart |
| SLDB | ▲ Buy | Option Exercise | 28,612 | — | 12/2/2023 | View on chart |
| SLDB | ▲ Buy | Grant | 584 | — | 12/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SLDB Featured in After-Market Movers List
Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.
SLDB Featured in After-Market Movers List. Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.